Against a backdrop of tight supplies of blood-derived medicinal products, the ANSM’s temporary specialized scientific committee has prioritized the indications for polyvalent human immunoglobulins as of May 31, 2018. Find out more on the ANSM.
Prioritization of indications for human polyvalent immunoglobulins